semaglutide and naion use in patients with diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, 4 years. https://ja.ma/4iZkMeV Specialists discuss concerns over impact

New trials emphasize consistent fat loss across weeks, with some patients shedding as much as 24% of body weight within a year

Please consult your healthcare provider before starting or changing any medication

As a unimolecular triple agonist, it targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors

Most patients starting with normal b12 levels and no significant risk factors do not require supplementation

As ongoing research addresses current challenges, GLP-1RAs are poised to play a significant role in the future management of neurodegenerative and neuroinflammatory diseases